Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc., as noted in the metadata request) on April 22, 2012. The report details the entry into a material definitive agreement to raise capital through a private placement of securities, which closed on April 25, 2012.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $3,124,000.
- Net Proceeds: Approximately $2,870,581 (after deducting placement agent commissions and estimated offering expenses).
- Placement Agent Fees: $218,680 paid to Rodman & Renshaw, LLC.
- Securities Issued:
- 2,360,001 shares of common stock.
- 1,000 shares of Series A 0% Convertible Preferred Stock (stated value $1,000 per share).
- Warrants to purchase up to 3,471,112 shares of common stock.
- Warrant Terms: Initial exercise price of $1.18 per share; not exercisable for six months; 2.5-year exercise term.
- Preferred Stock Conversion: Initial conversion price of $0.90 per share, allowing conversion into approximately 1,111 common shares per preferred share.
Material Changes and Use of Proceeds
The filing represents a significant capital raise event rather than a periodic financial performance report. The company intends to use the net proceeds for the following purposes:
- Funding clinical and regulatory programs for a potential "Scar Reduction" indication.
- Initiating additional regulatory filings to expand antimicrobial indications with the FDA in the surgical market.
- Meeting working capital needs and general corporate purposes.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the company's intentions and expectations for future activities. Management notes that actual outcomes may differ materially due to risks and uncertainties discussed in their Form 10-K. The filing does not provide specific financial guidance, revenue forecasts, or profit margins. The transaction was conducted pursuant to a shelf registration statement (File No. 333-171411) declared effective on May 3, 2011.
Key Facts for Investor Verification
- Verify the exact number of shares outstanding post-issuance to assess dilution impact.
- Confirm the status of the "Scar Reduction" and antimicrobial regulatory filings mentioned as uses of proceeds.
- Review the full Certificate of Designation (Exhibit 4.2) for specific adjustment mechanisms regarding the Series A Preferred Stock conversion price.
- Note that the filing text does not provide current revenue, profit, cash flow, or debt levels; these metrics are absent from this specific 8-K report.